Peptide Graded

Tesamorelin (compounded)

Does Tesamorelin (compounded) work?

Partly: some human trials, with gaps. For people without HIV, one trial of 60 adults.

BSome human evidenceNot approvedas of 2026-10-26

For the approved HIV indication the evidence would be A: two phase 3 placebo-controlled trials (412 and 404 patients, pooled 806) showed visceral fat fell about 15% over 26 weeks. For the use compounded tesamorelin is actually sold for, belly fat in people without HIV, there is one randomized trial of 60 abdominally obese adults with low GH secretion, and a 61-person trial in HIV-related fatty liver. That is B. 82967

The 2007 NEJM trial (412 patients) studied abdominal fat buildup linked to HIV. Over 26 weeks, visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo. Triglycerides and the cholesterol-to-HDL ratio also improved. A second trial of 404 patients and a pooled analysis of both (806 patients) gave a treatment effect of about -15.4% at 26 weeks. It held to 52 weeks in those who kept going. 829

The effect reverses. Patients who switched from tesamorelin to placebo at six months lost their visceral-fat improvement within the next six months. 24

Evidence checklist

  • Randomised controlled trial Two phase 3 RCTs; 60-person trial without HIV
  • Human study over 100 people Phase 3 trials pooled 806 patients
  • More than one research group Article does not say who ran the trials
  • Clinical outcomes, not surrogate markers Visceral fat measured, not health outcomes
  • Human safety data beyond case reports Phase 3 safety data; IGF-1 monitoring advised

Read the full Tesamorelin (compounded) page

More on Tesamorelin (compounded)

Citations

  1. DailyMed: Egrifta SV (tesamorelin) prescribing information dailymed.nlm.nih.gov
  2. Falutz 2010, J Acquir Immune Defic Syndr: tesamorelin in HIV abdominal fat accumulation, RCT with extension pubmed.ncbi.nlm.nih.gov
  3. DailyMed: Egrifta WR (tesamorelin) prescribing information dailymed.nlm.nih.gov
  4. Falutz 2008, AIDS: long-term safety and effects of tesamorelin, extension study doi.org
  5. FDA label, 2025: Egrifta WR accessdata.fda.gov
  6. Makimura 2012, J Clin Endocrinol Metab: tesamorelin in obese subjects with reduced GH secretion, RCT pubmed.ncbi.nlm.nih.gov
  7. Stanley 2019, Lancet HIV: tesamorelin for NAFLD in HIV, RCT pubmed.ncbi.nlm.nih.gov
  8. Falutz 2007, NEJM: metabolic effects of a GHRH analog in patients with HIV pubmed.ncbi.nlm.nih.gov
  9. Falutz 2010, J Clin Endocrinol Metab: pooled analysis of two phase 3 tesamorelin trials pubmed.ncbi.nlm.nih.gov
  10. Clemmons 2017, PLoS One: tesamorelin in type 2 diabetes, RCT pubmed.ncbi.nlm.nih.gov
  11. 2007, Basic Clin Pharmacol Toxicol: non-clinical pharmacology of TH9507 pubmed.ncbi.nlm.nih.gov

Reference information only, not medical advice. Drawn from the Tesamorelin (compounded) article, fact-checked against the cited sources. No dosing anywhere on this site.